GLP-1 drugs are driving major weight loss trends, but doctors warn that rapid weight loss may affect nutrition, bone density, heart health, and blood sugar balance.

In January, Novo Nordisk (NYSE: NVO) broke new ground in the weight-loss market by launching an oral version of its famous anti-obesity drug, Wegovy. It's the first oral GLP-1 approved for chronic ...

Up Another 13% 4 hours ago Live Shares of HIMS are up another 13%, or by $3.10, on news that Novo Nordisk agreed to distribute its products through the Hims platform, ending a longstanding feud ...

Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29.

Hims & Hers Health, Inc.'s revenue is projected to reach $2.7B in 2026 & $3.2B in 2027, implying less than 2x forward sales. Read more on HIMS stock here.

As an increasing number of patients come forward with claims that their vision has been permanently impacted by weight loss jabs, eye experts have issued a vital statistical warning. Back in February, ...

The Food and Drug Administration sent a warning letter to the makers of Ozempic and Wegovy for not reporting potential side ...

The FDA said it is giving Novo Nordisk two weeks to notify it of the actions it will take to prevent future violations. In a ...

Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images Ischemic optic neuropathy (ION), known ...

The FDA warned Novo Nordisk over reporting violations related to the deaths of patients taking its weight-loss drug.

Wegovy users have five times the risk of experiencing permanent sight loss linked to weight loss jabs than those taking other GLP-1 medications.

Drugs based on semaglutide have become some of the most talked-about medicines in recent years. These drugs belong to a class ...